(ANSA) - ROME, FEBRUARY 17 - For those who have had actual Covid-19, a single dose of Pfizer's vaccine would be enough to achieve protection equivalent to that given by the two full doses administered to the general population.
This is the conclusion of an Israeli study reported by the US media on the so-called "hybrid immunity".
The research noted that there was no difference in the protection against SARS-cov2 afforded by two doses or a single dose of Pfizer in those who had already been ill with covid.
According to the lead author of the study, Ronen Arbel, of Clalit Health Services, the vaccine provides an extra layer of protection in former patients and extends the duration of immunity, but "if someone has already had the infection, it is as if they have had a first dose of vaccine. At that point you have to vaccinate yourself. But only once. "
Commenting on the report, Shane Crotty, professor and virologist at the Center for Infectious Diseases and Vaccines at the La Jolla Institute for Immunology, noted that it would be "reasonable" to adopt new measures so that people who have already been affected by Covid receive only one. vaccine dose.
(HANDLE).
